Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $17.0 million.

  • Iovance Biotherapeutics' Cash from Investing Activities rose 13485.99% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.4 million, marking a year-over-year increase of 13648.83%. This contributed to the annual value of -$96.4 million for FY2024, which is 3789.63% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Cash from Investing Activities of $17.0 million as of Q3 2025, which was up 13485.99% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cash from Investing Activities ranged from a high of $153.4 million in Q1 2023 and a low of -$156.8 million during Q2 2023
  • For the 3-year period, Iovance Biotherapeutics' Cash from Investing Activities averaged around -$18.6 million, with its median value being $13.8 million (2025).
  • In the last 5 years, Iovance Biotherapeutics' Cash from Investing Activities plummeted by 17269.16% in 2024 and then skyrocketed by 13485.99% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Cash from Investing Activities stood at -$72.8 million in 2023, then surged by 132.5% to $23.7 million in 2024, then decreased by 28.15% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q3 2025, $13.8 million for Q2 2025, and $15.9 million during Q1 2025.